A new drug combo recently approved by the Food & Drug Administration can halt lung cancer in its treacherous tracks — for ...
The FDA has granted approval for Novocure‘s wearable medical device, Optune Lua, designed to treat advanced non-small cell ...
First targeted treatment to reduce the risk of ALK positive lung cancer returning after complete tumour removal recommended ...
When you think of lung cancer treatment, what comes to mind—chemotherapy, radiation, surgery? While these can be crucial, ...
Alongside immunotherapy or chemo, the wearable device helped patients live longer in a trial, though the results are somewhat controversial.
Novocure Ltd (NASDAQ:NVCR) shares soared sharply after the announcement that the FDA had approved Optune Lua, a wearable ...
When I was diagnosed with lung cancer, I didn’t want to receive chemotherapy, especially when I was a good candidate for ...
Novocure (NASDAQ: NVCR) announced today that the U.S. Food and Drug Administration (FDA) has approved Optune Lua® for ...
What’s more, AM-101 improved radiation treatment, slowing down the growth of NSCLC subcutaneous xenograft tumors in mice, by ...
Novocure announced on Tuesday that the FDA treated its Optune Lua wearable device for treating metastatic non-small cell lung ...
Novocure received a long-sought FDA approval for the use of its Tumor Treating Fields technology against metastatic non-small ...